Root Cause Analysis in CAR-T Manufacturing
/ Data-Driven Manufacturing

Root Cause Analysis in CAR-T Manufacturing: Solving Slow Cell Growth

Root Cause Analysis in CAR-T Manufacturing: Solving Slow Cell Growth
  • Identify factors contributing to slow cell growth
  • Improve CAR-T manufacturing consistency and predictability
  • Strengthen data traceability and audit readiness

Optimizing CAR-T Yields

Download the white paper

By submitting your details, you agree to our Privacy Policy , and to receive email communications from Mareana. You may unsubscribe at any time.

Key Takeaways

With Mareana, you can connect patient, process, and manufacturing data to identify the root causes of slow growth, improve CAR-T yields, and enhance manufacturing consistency.

In this whitepaper, you will learn
  • The primary causes of slow growth in CAR-T manufacturing

  • The impact of activation, modification, and culture conditions on yield

  • Why genealogy and contextualized manufacturing data are critical for root cause analysis

  • Strategies for improving consistency, scalability, and manufacturing performance in CAR-T production

Good Manufacturing
Practice

Connected Data Deep Insights.

Good Manufacturing
Practice

Connected Data Deep Insights.

/ ANY QUESTIONS? WE'D LOVE TO HELP

Frequently Asked Questions

Slow growth in CAR-T manufacturing occurs when T cells fail to proliferate efficiently during the expansion phase, resulting in lower cell yields and production delays. Common causes include patient-specific factors, inefficient cell activation and genetic modification processes, suboptimal culture conditions, and cell senescence. Identifying these root causes is critical for improving manufacturing consistency and ensuring timely delivery of CAR-T therapies.

Manufacturers can identify the root cause of slow growth by leveraging integrated manufacturing data, advanced analytics, and machine learning. A data-driven approach enables teams to analyze patient data, process conditions, cell modification parameters, and culture environments to uncover hidden patterns and correlations that impact cell proliferation. This allows for targeted interventions that improve production outcomes and reduce batch failures.

Culture conditions play a critical role in CAR-T cell growth and expansion. Factors such as media composition, oxygen levels, nutrient availability, temperature, and pH directly influence cell proliferation and viability. Even small variations in these parameters can reduce cell yields and impact manufacturing success. Real-time monitoring and optimization of culture conditions help maintain consistent growth and improve product quality.

Machine learning improves CAR-T manufacturing by analyzing large volumes of process data to identify patterns, predict growth outcomes, and detect anomalies before they become critical issues. Predictive models can forecast the likelihood of slow growth, allowing manufacturers to proactively adjust process parameters and prevent batch failures. This leads to higher yields, better consistency, and more efficient manufacturing operations.

A data-driven approach helps CAR-T manufacturers improve patient outcomes, increase cell yields, reduce batch variability, and lower production costs. By identifying the factors contributing to slow growth, manufacturers can optimize processes, minimize rework, improve regulatory compliance, and ensure more reliable delivery of therapies. Enhanced traceability and predictive analytics also support continuous process improvement.

Mareana provides a comprehensive platform for integrating manufacturing, patient, and process data into a single genealogy. Using advanced analytics, machine learning, and root cause analysis capabilities, the platform helps manufacturers identify the factors driving slow growth, predict potential issues, and optimize production conditions. This enables proactive decision-making, reduces batch failures, and improves overall manufacturing efficiency and consistency.

Lessons from the First FDA Warning Letter on AI Misuse
/ BEFORE YOU GO

Lessons from the First FDA Warning Letter on AI Misuse

By signing up, you agree to the Privacy Policy.